ARTICLE | Clinical News
Amantadine: Phase II data
July 18, 2016 7:00 AM UTC
Top-line data from 56 MS patients with walking impairment in the modified intent-to-treat (mITT) population of a double-blind, U.S. Phase II trial showed that once-daily 340 mg oral ADS-5102 for 4 wee...